Global Botulinum Toxin Market

Botulinum Toxin Market Size, Share, Growth Analysis, By Type(Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use(Aesthetic, Therapeutics) - Industry Forecast 2024-2031


Report ID: SQMIG35I2220 | Region: Global | Published Date: July, 2001
Pages: 165 | Tables: 61 | Figures: 75

Botulinum Toxin Market Competitive Landscape

The key players in the botulinum toxin market are working on continuous innovation and product portfolio enhancement for better aesthetic and therapeutic outcomes for patients. For example, in February 2021, AbbVie, one of the prominent players in global botulinum toxin market, got FDA clearance for Botox to treat detrusor overactivity associated with a neurological disease in select pediatric patients aged 5 and older. Furthermore, the growing relevance of aesthetic beauty, fueled by the expanding therapeutic applications of these toxins for critical and chronic diseases, is expected to drive the growth of botulinum toxin during the forecast period.

Top Players in Botulinum Toxin Market

  • Allergan
  • Ipsen
  • Merz Pharma
  • Medytox
  • Revance Therapeutics
  • US WorldMeds
  • Galderma
  • Hugel
  • Suneva Medical
  • Daewoong Pharmaceutical
  • Mylan
  • Evolus
  • Teijin Pharma
  • Anterios Inc.
  • Canbex Therapeutics
  • Lanzhou Institute of Biological Products
  • Eisai
  • SciClone Pharmaceuticals
  • InMed Pharmaceuticals
  • Syneron Medical

Recent Development in Global Botulinum Toxin Market

  • In April 2022, PatientFi, an emerging company in patient payments, announced expansion of its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX Cosmetic (onabotulinumtoxinA), JUVÉDERM Collection of Fillers, Natrelle breast implants for breast augmentation, CoolSculpting, and DiamondGlow.
  • In February 2022, Healis Therapeutics announced that its its ownership of a crucial botulinum toxin patent from AbbVie. Allergan obtained the rights to develop botulinum toxin for depression in 2013 after clinically significant outcomes in early trials. In 2017, Allergan completed a Phase II study and announced intentions for a Phase III investigation. AbbVie obtained control after acquiring Allergan in 2020.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Botulinum Toxin Market size was valued at USD 5.8 billion in 2019 and is poised to grow from USD 6.47 billion in 2023 to USD 17.23 billion by 2031, growing at a CAGR of 11.5% in the forecast period (2024-2031).

The key players in the botulinum toxin market are working on continuous innovation and product portfolio enhancement for better aesthetic and therapeutic outcomes for patients. For example, in February 2021, AbbVie, one of the prominent players in botulinum toxin market, got FDA clearance for Botox to treat detrusor overactivity associated with a neurological disease in select pediatric patients aged 5 and older. Furthermore, the growing relevance of aesthetic beauty, fueled by the expanding therapeutic applications of these toxins for critical and chronic diseases, is expected to drive the growth of botulinum toxin during the forecast period. 'Allergan', 'Ipsen', 'Merz Pharma', 'Medytox', 'Revance Therapeutics', 'US WorldMeds', 'Galderma', 'Hugel', 'Suneva Medical', 'Daewoong Pharmaceutical', 'Mylan', 'Evolus', 'Teijin Pharma', 'Anterios Inc.', 'Canbex Therapeutics', 'Lanzhou Institute of Biological Products', 'Eisai', 'SciClone Pharmaceuticals', 'InMed Pharmaceuticals', 'Syneron Medical'

Rising Demand for Minimally Invasive Cosmetic Procedures to Drive Botulinum Toxin Market

Women accounted for 92% of all cosmetic procedures performed around the globe while only 8 males undergo cosmetic procedures

North America dominated the botulinum toxin market in 2021, owing to the region's highly aware and economically stable population, as well as a significantly higher number of procedures conducted in the US and Canada. In 2021, more than 3.6 million cosmetic procedures involving neurotoxins (such as Botox) were performed. The increasing availability of numerous non-invasive cosmetic treatments and frequent new product approvals for a wide range of therapeutic indications are expected to fuel the expansion of botulinum toxin market over the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Botulinum Toxin Market

Product ID: SQMIG35I2220

$5,300
BUY NOW GET FREE SAMPLE